Premium
Toward clinical trials of DNA vaccines against malaria
Author(s) -
Hoffman Stephen L,
Doolan Denise L,
Sedegah Martha,
Wang Ruobing,
Scheller Libia F,
Kumar Anita,
Weiss Walter R,
Le Thong P,
Klinman Dennis M,
Hobart Peter,
Norman Jon A,
Hedstrom Richard C
Publication year - 1997
Publication title -
immunology and cell biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.999
H-Index - 104
eISSN - 1440-1711
pISSN - 0818-9641
DOI - 10.1038/icb.1997.59
Subject(s) - immunogenicity , circumsporozoite protein , dna vaccination , malaria vaccine , plasmodium falciparum , malaria , virology , biology , immunology , medicine , immunization , antigen
In mid 1997 the first malaria DNA vaccine will enter clinical trials. This single gene DNA vaccine encoding the Plasmodium falciparum circumsporozoite protein (PfCSP) will be studied for safety and immunogenicity. If these criteria are met, a multi‐gene DNA vaccine designed to induce protective CDS8 + T cell responses against P. falciparum infected hepatocytes will be subsequently assessed for safety, immunogenicity and capacity to protect immunized volunteers against experimental challenge with P. falciparum sporozoites. Our perspectives on malaria vaccine development in general, 1 and on a multi‐gene DNA vaccine in particular, 2 have been recently reviewed. Herein, we review the rationale and experimental foundation for the anticipated P. falciparum DNA vaccine trials.